Download Files:
Products Details
Product Description
– AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research[1][2].
Web ID
– HY-111245
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C22H31FN4O4
References
– [1]Alexander Burashnikov, et al. AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol. 2010 Jul;56(1):80-90. |[2]Charles Antzelevitch, et al. AZD1305 Exerts Atrial Predominant Electrophysiological Actions and Is Effective in Suppressing Atrial Fibrillation and Preventing Its Reinduction in the Dog. [J] Cardiovasc Pharmacol. 2010, Volume 56，Number 1. |[3]Serge Sicouri, et al. Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2010, Volume 334，Number 1.
CAS Number
– 872045-91-5
Molecular Weight
– 434.50
SMILES
– O=C(OC(C)(C)C)NCCN1CC(O2)CN(CCOC3=CC=C(C#N)C=C3F)CC2C1
Clinical Information
– No Development Reported
Research Area
– Neurological Disease; Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– Calcium Channel;Potassium Channel;Sodium Channel
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
